Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: A facility based cross-sectional study

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Alemayehu, Mekuriaw ^a   Wubshet, Mamo ^b   Mesfin, Nebiyu ^a   Gebayehu, Abebaw ^a  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b ST PAUL S HOSPITAL MILLENNIUM MEDICAL COLLEGE   (Ethiopia)

Author keywords

Coinfection; Human immunodeficiency virus; Northwest Ethiopia; Visceral Leishmaniasis

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CROSS-SECTIONAL STUDY; EMPLOYMENT; ETHIOPIA; FEMALE; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PARASITOLOGY; PREVALENCE; RESIDENTIAL AREA; RISK FACTOR; SCHOOL CHILD; SERODIAGNOSIS; URBAN POPULATION; VISCERAL LEISHMANIASIS; WORKER; YOUNG ADULT; CLINICAL TRIAL; COINFECTION; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; LEISHMANIASIS, VISCERAL; MANAGEMENT; MULTICENTER STUDY; QUESTIONNAIRE; STATISTICAL MODEL; VIROLOGY;

ADOLESCENT; ADULT; CHILD; COINFECTION; CROSS-SECTIONAL STUDIES; ETHIOPIA; FEMALE; HIV; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; LOGISTIC MODELS; MALE; MIDDLE AGED; POLICY MAKING; PREVALENCE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85013029083     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2261-8     Document Type: Article

References (31)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239-43.
2. WHO: Visceral Leishmaniasis. http://www.who.int/leishmaniasis/visceral_leishmaniasis/en/ 2016.
3. Wolday D, Akuffo H, Demissie A, Britton S. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun. 1999;67:5258-64.
4. Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/HIV co-infections in the second decade. Indian J Med Res. 2006;123:357-88.
5. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97 Suppl 1:3-15.
6. Alvar J, Aparicio P, Assefa A, Den Boer M, Canavate C, Dedet JP, et al. The Relationship between Leishmaniasis and AIDS: the second 10 years. Clin Microb Rev. 2008;21(2):334-59.
7. Horst TR, Colline SM, Ritemeijer K, Bogale A, Davidson NR. Concordant HIV infection and Visceral Leishmaniasis in Ethiopia: The influence of Antiretroviral Treatment and other factors on outcome. Clin Infect Dis. 2008;46:1702-9.
8. WHO: HIV/AIDS progress in 2014. wwwafrowhoint/en/ethiopia/who-country-office-ethiopiahtml 2015.
9. Ermias D, Lutgarde L, Koert R, Marleen B, Asrat H, Van G. Visceral Leishmaniasis and HIV Coinfection in East Africa. PLoS Negl Trop Dis. 2014;8:6.
10. Mulat Y, Bayeh A, Wondemagegn M, Yohannes Z, Belay B. Proportional of Visceral Leishmaniasis and Human immune deficiency virus co-infection among clinically confirmed visceral leishmaniasis patients at the endemic foci of the Amahara National Regional State, North-West Ethiopia. Am J Biol Life Sci. 2014;2(1):1-7.
11. Gradoni L, Scalone A, Gramiccia M, Troiani M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS. 1996;10:785-91.
12. Medrano F, Herna'ndez-Quero J, Jime'nez E, Pineda J, Rivero A, Sa'nchez-Quijano A, et al. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS. 1992;6:1499-503.
13. Amela C, Lo'pez-Gay D, Alberdi J, Castilla J. Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients. Eur J Epidemiol. 1996;12:91-2.
14. PINEDA JA GALLARDOJA, AS JM, DELGADO J, REGORDA'N C, MORILLAS F, et al. Prevalence of and Factors Associated with Visceral Leishmaniasis in Human Immunodeficiency Virus Type 1-Infected Patients in Southern Spain. J Clini Microbiol. 1998;36:9.
15. Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, et al. Incidence of and Risk Factors for Symptomatic Visceral Leishmaniasis among Human Immunodeficiency Virus Type 1-Infected Patients from Spain in the Era of Highly Active Antiretroviral Therapy. J Clini Microbiol. 2002;40:3.
16. Mengistu G, Ayele B. Visceral leishmaniasis and HIV co-infection in patients admitted to Gondar University Hospital, North West Ethiopia. Ethiop J Health Dev. 2007;21:53-60.
17. FMOH: guideline for diagnosis, treatment and prevention of Leishmaniasis in Ethiopia. 2013. http://www.moh.gov.et/.
18. WHO. Manual on visceral leishmaniasis. Geneva: Report WHO/Leish/9640; 1996.
19. Meredith S, Kroon NC, Sondorp E, et al. Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis. J Clin Microbiol. 1995;33:1742-5.
20. WHO. Technical, report: Control of the leishmaniasis. Geneva: Report of a meeting of the WHO expert committee; 2010.
21. FMOH. Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. Addis Ababa: Federal HIV/AIDS prevention and control office and Federal Minsitry of Health; 2007.
22. Sullivan M, Zuguo M, Grummer-Strawn L, Ibrahim P. Haemoglobin adjustments to define anaemia. Trop Med Int Health. 2008;13(8):1267-71.
23. Guerin PJ, Piero O, Shyam S, Marleen B, Croft SL, Philippe D, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494-501.
24. Lindoso J, Cota GF, Da Cruz AM, Goto H, Maia-Elkhoury ANS, et al. Visceral Leishmaniasis and HIV Coinfection in Latin America. PLoS Negl Trop Dis. 2014;8(9), e3136. doi: 10.1371/journal.pntd.0003136.
25. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg. 2001;95:668-72.
26. Hailu A, Gebre-Michael T, Berhe N, Balkew M. Leishmaniasis in Ethiopia: The Ecology and Epidemiology of Health and Disease in Ethiopia. Addis Ababa: Shama Books; 2006. p. 615-34.
27. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al.: Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health. 2010;15:848-55. doi: 10.1111/j1365-3156201002550x.
28. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health. 2003;8:733-9.
29. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al.: A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43:357-64. doi: 10.1086/505217.
30. FMOH: Ethiopia National Malaria Indicator Survey 2011: Technical Summary. Addis Ababa, Ethiopia pp 1-11 2011. http://www.moh.gov.et/.
31. FMOH: Health extension program in Ethiopia. Addis Ababa, Ethiopia. 2007 http://www.moh.gov.et/.